Prioritized research recommendations from the <scp>N</scp>ational <scp>I</scp>nstitute of <scp>N</scp>eurological <scp>D</scp>isorders and <scp>S</scp>troke <scp>P</scp>arkinson's<scp>D</scp>isease 2014 conference

Sieber, Beth-Anne; Landis, Story C.; Koroshetz, Walter J.; Bateman, Randall J.; Siderowf, Andrew; Galpern, Wendy R.; Dunlop, John; Finkbeiner, Steven; Sutherland, Margaret; Wang, Hao; Lee, Virginia M.‐Y.; Orr, Harry T.; Gwinn‐Hardy, Katrina; Ludwig, Kip A.; Taylor, Anna; Torborg, Christine L.; Montine, Thomas J.

doi:10.1002/ana.24261

Cited by 86 publications

(70 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 We believe the development of the PRO-PD is one step towards that goal and offers a simple, low cost means to measure both the motor and non-motor symptoms of PD.…”

Section: Discussionmentioning

confidence: 99%

Use of a self-rating scale of the nature and severity of symptoms in Parkinson’s Disease (PRO-PD): Correlation with quality of life and existing scales of disease severity

Mischley

Lau

Weiss

2017

npj Parkinson's Disease

View full text Add to dashboard Cite

A self-rating scale was developed to permit patient-reported, remote assessment of Parkinson’s disease symptom severity. The goal was to create a continuous outcome measure that does not require a clinical exam, does not fluctuate in response to dopaminergic medications, takes only a few minutes to complete, allows for stratification by symptom(s), and captures both motor and non-motor Parkinson’s disease symptoms, major contributors to quality of life. The Patient Reported Outcomes in Parkinson’s Disease (PRO-PD) is the cumulative score of 32 slider bars, each evaluating a common Parkinson’s disease symptom. The PRO-PD has been used as an outcome measure in three studies. The baseline data from each of these studies were pooled for this analysis. Symptom frequency and severity are described, as well as correlation coefficients with existing measures of Parkinson's disease severity. Data on 1031 participants with Parkinson's disease were available for analysis. Fatigue, impaired handwriting, daytime sleepiness, slowness, tremor, muscle cramps, and forgetfulness were the most frequently reported symptoms. Persons with a relatively long duration of Parkinson's disease tended to report more, and more severe, symptoms. The PRO-PD was most highly correlated with the Parkinson’s Disease Questionaire-39 (r = 0.763, P < 0.000) and Patient-Reported Outcome Measurement Information System Global quality of life (r = −0.7293, P < 0.000), other patient-reported quality of life measures. The PRO-PDnon-motor subset was highly correlated with the Non-Motor Symptom Score (r = 0.7533, P < 0.000). There was a moderate correlation seen with Hoehn & Yahr (r = 0.5922, P < 0.000), total Unified Parkinson’s disease Rating Scale (r = 0.4724, P < 0.000), and the Timed-Up-&-Go (r = 0.4709, P < 0.000). The PRO-PD may have utility for patients, providers, and researchers as a patient-centered measure of Parkinson’s disease symptom severity. Further PRO-PD validation efforts are warranted.

show abstract

“…19 We believe the development of the PRO-PD is one step towards that goal and offers a simple, low cost means to measure both the motor and non-motor symptoms of PD.…”

Section: Discussionmentioning

confidence: 99%

Use of a self-rating scale of the nature and severity of symptoms in Parkinson’s Disease (PRO-PD): Correlation with quality of life and existing scales of disease severity

Mischley

Lau

Weiss

2017

npj Parkinson's Disease

View full text Add to dashboard Cite

show abstract

“…There is an increasing acknowledgement of the clinical heterogeneity of idiopathic Parkinson’s disease (Selikhova et al , 2009; Halliday et al , 2011; Sieber et al , 2014) and differences in survival rates have been reported between clinical subtypes defined in longitudinal analysis (de Lau et al , 2014). Visual dysfunction frequently co-exists with cognitive impairment, visual hallucinations, postural instability with gait disorder and RBD (Davidsdottir et al , 2005; Marques et al , 2010).…”

Section: Clinical Relevancementioning

confidence: 99%

Visual dysfunction in Parkinson’s disease

Weil

Schrag

Warren

et al. 2016

Brain

357

285

View full text Add to dashboard Cite

show abstract

“…There are marked differences between presentations, clinical courses, and rates of progression of the disease in people with PD. Understanding the biological bases of the wide disparities in development and evolution of the multiple manifestations of PD has been recognized as a major goal for PD research . The underlying assumption is that there are biologically distinct subtypes of PD with different genetic and environmental etiologies and with distinct pathologies, which will require different disease‐modifying and symptomatic treatments.…”

Section: Importance Of Subtypesmentioning

confidence: 99%

Motor subtype in Parkinson's disease: Different disorders or different stages of disease?

Nutt

2016

Mov Disord.

103

View full text Add to dashboard Cite

Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson'sDisease 2014 conference

Cited by 86 publications

References 8 publications

Use of a self-rating scale of the nature and severity of symptoms in Parkinson’s Disease (PRO-PD): Correlation with quality of life and existing scales of disease severity

Use of a self-rating scale of the nature and severity of symptoms in Parkinson’s Disease (PRO-PD): Correlation with quality of life and existing scales of disease severity

Visual dysfunction in Parkinson’s disease

Motor subtype in Parkinson's disease: Different disorders or different stages of disease?

Contact Info

Product

Resources

About